https://doi.org/10.4081/gimle.559

[Monoclonal gammopathy of uncertain significance (MGUS) and occupational risk factors: criteria for implementing health surveillance]

Vol. 41 No. 3 (2019)
Published: February 20 2025
Abstract Views: 44
PDF: 24
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Giuseppe Taino
Unità Operativa Ospedaliera di Medicina del lavoro (UOOML), Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
Lorenzo Bordini
Fondazione IRCCS Policlinico Ca’ Granda Ospedale Maggiore, Milano, Italy.
Cecilia Sarto
Azienda Ospedaliera di Desio e Vimercate (MI), Italy.
Sara Porro
Azienda Ospedaliera di Desio e Vimercate (MI), Italy.
Francesco Chirico
Servizio Sanitario della Polizia di Stato, Ministero dell’Interno, Milano, Italy.
Enrico Oddone
enrico.oddone@unipv.it
Dipartimento di Sanità Pubblica, Medicina Sperimentale e Forense, Università degli Studi di Pavia e IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy.
Marcello Imbriani
Dipartimento di Sanità Pubblica, Medicina Sperimentale e Forense, Università degli Studi di Pavia e IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy.

Introduction. Monoclonal gammopathy of uncertain significance (MGUS) identifies a clinically asymptomatic and laboratory-based situation characterized by a modest monoclonal component (MC). In a limited percentage of cases, on a probabilistic basis, the asymptomatic premalignant stage could lead to multiple myeloma (MM).
Materials and Methods. Based on literature data and available Guidelines on the subject, the diagnostic criteria and a methodological path are here suggested to the Occupational Physician to formulate a judgment of suitability for the task with exposure risk to RI or pesticides.
Results. Some studies have evaluated the prevalence of MGUS in subjects exposed professionally to pesticides. Numerous other studies conducted on the survivors of the atomic bombing of Hiroshima and Nagasaki have highlighted a possible association with exposure to ionizing radiation (IR). The guidelines relating to the diagnosis and management of MGUS cases (with respect to the potential evolution in MM allow) to draw important operational indications for the competent/authorized physician. Conclusions. The routinely use of laboratory tests for subjects exposed to the studied risk factors is generally indicated starting from the worker's 50 years of age. The finding of a MGUS in the absence of further laboratory alterations represents the situation most frequently and does not require further measures, other than those of foreseeing even blood controls at least every two years. In this situation, there are no justified restrictions on work activities with exposure risks to IR or pesticides.
If alterations suggestive for an increased risk of evolution in a neoplastic way could be identified, a close periodicity - every 3-6 months - of haematological checks is recommended. In these cases, it appears justified an abstention from activities involving exposure to ionizing radiation for a period of time that will be evaluated based on the evolution of the framework and by the progress of laboratory tests in the monitored period.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1) Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354(13): 1362-9. 2) Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150(1): 28-38. 3) Wadhera RK, Rajkumar SV. Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Mayo Clin Proc 2010; 85(10): 933-942. DOI: https://doi.org/10.4065/mcp.2010.0337
4) Kyle RA, Rajkumar SV. Epidemiology of the plasma-cel disorders. Best Pract Res Clin Haematol 2007; 20(4): 637-64. DOI: https://doi.org/10.1016/j.beha.2007.08.001
5) Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007; 82: 1468-73. DOI: https://doi.org/10.1016/S0025-6196(11)61089-6
6) Saberi Hosnijeh F, Christopher Y, Peeters P, Romieu I, Xun W, Riboli E, et al. Occupation and risk of lymphoid and myeloid leukaemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). Occup Environ Med 2013; 70: 464-470. 7) Pasqualetti P, Casale R, Colantonio D, Collacciani A. Occupational risk for hematological malignancies. Am J Hematol 1991; 38: 147-149. DOI: https://doi.org/10.1002/ajh.2830380216
8) International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the IMWG. Br Haematol 2003; 121: 749-57. DOI: https://doi.org/10.1046/j.1365-2141.2003.04355.x
9) International Myeloma Working Group update criteria for the diagnosis of multiple myeloma. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. Lancet Oncol 2014; 15: 538-48.
10) Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ, 3rd, Colby CL, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375: 1721-8. DOI: https://doi.org/10.1016/S0140-6736(10)60482-5
11) Pasqualetti P, Collacciani A, Casale R. Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am J Hematol 1996 Jul; 52(3): 217-20. DOI: https://doi.org/10.1002/(SICI)1096-8652(199607)52:3<217::AID-AJH15>3.0.CO;2-C
12) Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 2009; 113(25): 6386-91. DOI: https://doi.org/10.1182/blood-2009-02-203471
13) Landgren O, Shim YK, Michalek J, Costello R, Burton D, Ketchum N, et al. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study. JAMA Oncol 2015; 1(8): 1061-8. DOI: https://doi.org/10.1001/jamaoncol.2015.2938
14) Neriishi K, Nakashima E, Suzuki G. Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. British Journal of Haematology 2003; 121(3): 405-410. DOI: https://doi.org/10.1046/j.1365-2141.2003.04287.x
15) Iwanaga M, Tagawa M, Tsukasaki K, Matsuo T, Yokota K, Miyazaki Y, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposur in Nagasaki atomic bomb survivors. Blood 2009; 113(8): 1639-50. DOI: https://doi.org/10.1182/blood-2008-05-159665
16) Iwanaga M, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significancein Asia: a viewpoint from nagasaki atomic bomb survivors. Clin Lymphoma Myeloma Leuk 2014; 14(1): 18-20. DOI: https://doi.org/10.1016/j.clml.2013.12.010
17) Sirohi B, Powles R. Epidemiology an outcomes research for MGUS myeloma and amyloidosis. Eur J Cancer 2006; 42(11): 1671-83. 18) Pasqualetti P, Festuccia V, Acitelli P, Collacciani A, Giusti A, Casale R. Tobacco smoking and risk of haematological malignancies in adults: a case-control study. Br J Haematol 1997; 97(3): 659-62 19) Ramchandren S, Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep 2012; 12(1): 102-10. DOI: https://doi.org/10.1046/j.1365-2141.1997.942910.x
20) Théaudin M, Lozeron P, Lacroix C, Chrétien P, Ducot B, Denier C, Adams D. Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study. Rev Neurol (Paris) 2011; 167(12): 897-904. DOI: https://doi.org/10.1016/j.neurol.2011.04.005
21) Za T, De Stefano V, Rossi E, Petrucci MT, Andriani A, Annino L, et al. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. Br J Haematol 2013; 160(5): 673-9. 23) Taino G, Cornaggia E, Fioramonti B, Imbriani M. La denuncia di sospetta tecnopatia: novità e criticità normative, suggerimenti applicativi. G Ital Med Lav Ergon 2017; 39(1): 5-15. DOI: https://doi.org/10.1111/bjh.12168
24) Taino G, Paraluppi P, Giorgi M, D'Orso MI, Piccoli B. Le malattie professionali da radiazioni ottiche artificiali (ROA). Med Lav 2013; 104(1): 3-23.
25) Associazione Italiana Radioprotezione Medica, Linee guida AIRM: sorveglianza medica dei lavoratori esposti a radiazioni ionizzanti. IPSOA, 2013.
26) Taino G, Giroletti E, Delogu A, Malagò G, Corona G, Businaro J, Imbriani M. Il giudizio di idoneità al rischio da esposizione a radiazioni ionizzanti nei lavoratori con pregressa patologia neoplastica: criteri di valutazione e analisi di una casistica. Med Lav 2014; 105(6): 445-472.

How to Cite



[Monoclonal gammopathy of uncertain significance (MGUS) and occupational risk factors: criteria for implementing health surveillance]. (2025). Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia, 41(3), 202-207. https://doi.org/10.4081/gimle.559
Copyright (c) 2019 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Most read articles by the same author(s)

<< < 1 2 3 > >>